Search
Cyclopentolate
go.drugbank.com/drugs/DB00979ApprovedA parasympatholytic anticholinergic used solely to obtain mydriasis or cycloplegia.
Norelgestromin
go.drugbank.com/drugs/DB06713ApprovedInvestigational[L63816] Combined hormonal contraceptives containing norelgestromin lower the risk of pregnancy primarily by suppressing ovulation.
Mixtures: Gwyn LoLenalidomide
go.drugbank.com/drugs/DB00480ApprovedInvestigational[A228708] Available as oral capsules, lenalidomide is approved by the FDA and EU for the treatment of multiple myeloma, myelodysplastic syndromes, mantle cell lymphoma, follicular lymphoma, and marginal … [L16028] Due to severe teratogenicity, pregnancy must be excluded before the start of treatment and patients must enroll in the lenalidomide Risk Evaluation and Mitigation Strategy (REMS) program to ensure
Enfortumab vedotin
go.drugbank.com/drugs/DB13007ApprovedInvestigational[L10836] Enfortumab vedotin was later approved by the European Commission on April 13, 2022.[L42000] … [L10836] It is similar to [brentuximab vedotin], another antibody conjugated with MMAE that targets CD-30 instead of Nectin-4.
Tafasitamab
go.drugbank.com/drugs/DB15044ApprovedInvestigationalrelative to non-engineered anti-CD19 antibodies. … [L15292,A191829] The CD19 surface protein is highly expressed on the surface of B-cells, where it appears to play a role in enhancing B-cell receptor signaling.
Erdafitinib
go.drugbank.com/drugs/DB12147ApprovedInvestigationalpersonalized treatment targeting susceptible FGFR genetic alterations for patients with metastatic bladder cancer, which demonstrates the development of more personalized and precise medicines tailoring to … Considering urothelial cancer is statistically the fourth most common kind of cancer in the world, the introduction of erdafitinib offers a much-needed new option in the ever-expanding therapeutic tool kit to
Dotatate gallium Ga-68
go.drugbank.com/drugs/DB13925ApprovedInvestigationalWithdrawn[A31358] Dotatate gallium 68 was developed by Advanced Accelerator Applications USA, Inc. and FDA approved in June 1, 2016. … Dotatate gallium (Ga-68) explotes its ability to detect somatostatin receptor scintigraphy and this characteristic tends to change with tumor grade which gives Ga-68 dotate a high diagnostic value.
Prednicarbate
go.drugbank.com/drugs/DB01130ApprovedIt has a favorable benefit-risk ratio, with an inflammatory action similar to that of a medium potency corticosteroid, but with a low potential to cause skin atrophy. … IL-1a is also found in fibroblasts, where it is responsible for proliferation, collagenase induction and IL-6 synthesis, which are related to skin thickness.
Givinostat
go.drugbank.com/drugs/DB12645ApprovedInvestigationalIn the context of muscular dystrophy, inhibitors of HDAC appear to exert their therapeutic effects by targeting pathogenic processes that cause inflammation and muscle loss. … [L50311,L50316] It is the first non-steroidal drug approved to treat patients with all genetic variants of DMD.[L50316]
Lecanemab
go.drugbank.com/drugs/DB14580ApprovedInvestigational[A253962,L44547] On January 6, 2023, lecanemab was granted accelerated approval by the FDA for the treatment of Alzheimer’s Disease.[L44547] It was granted full FDA approval on July 6, 2023. … [L44537] Lecanemab works to reduce Aβ plaques and prevent Aβ deposition in the brain [A253947,A253952] with high selectivity to Aβ protofibrils.